Hydroxychloroquine withdrawal triggers pregnancy-associated pulmonary arterial hypertension in systemic lupus erythematosus: a case report and exploration of the Complement-EndMT axis

This case provides compelling <i>in vivo</i> evidence that non-adherence to HCQ constitutes a pivotal, modifiable risk factor for the onset of SLE-associated PAH in the gravid state, and that pharmacological reintroduction can arrest and partially reverse this pathogenic trajectory. We attribute the vascular protective effects of HCQ to the inhibition of complement activation along the C5a-MAPK/ERK signaling axis. Targeting this pathway disrupts pathological endothelial-mesenchymal transition (EndMT) and mitigates subsequent pulmonary vascular remodeling. Stringent HCQ adherence should be standard of care. Furthermore, complement monitoring guides precision pharmacotherapy to prevent PAH in susceptible SLE pregnancies.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-03-02
DOI
https://doi.org/10.3389/fphar.2026.1778983
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hydroxychloroquine withdrawal triggers pregnancy-associated pulmonary arterial hypertension in systemic lupus erythematosus: a case report and exploration of the Complement-EndMT axis

L Zhang, Yufei Zhang, Qi Wei, Jinke Li et al.
Frontiers in Pharmacology
Pulmonary Hypertension Research and Treatments
article

Hydroxychloroquine withdrawal triggers pregnancy-associated pulmonary arterial hypertension in systemic lupus erythematosus: a case report and exploration of the Complement-EndMT axis

L Zhang, Yufei Zhang, Qi Wei, Jinke Li, Xue-feng JIAO (焦雪峰), Chun-Fei Wang
article en

Abstract

This case provides compelling <i>in vivo</i> evidence that non-adherence to HCQ constitutes a pivotal, modifiable risk factor for the onset of SLE-associated PAH in the gravid state, and that pharmacological reintroduction can arrest and partially reverse this pathogenic trajectory. We attribute the vascular protective effects of HCQ to the inhibition of complement activation along the C5a-MAPK/ERK signaling axis. Targeting this pathway disrupts pathological endothelial-mesenchymal transition (EndMT) and mitigates subsequent pulmonary vascular remodeling. Stringent HCQ adherence should be standard of care. Furthermore, complement monitoring guides precision pharmacotherapy to prevent PAH in susceptible SLE pregnancies.

Frontiers in PharmacologyVol. 17
National Medical Products Administration (CN), Sichuan University (CN), West China Second University Hospital of Sichuan University (CN)
Good health and well-being
Openalex Percentile: Top 37%
Pulmonary Hypertension Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.